Prospective Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2020; 12(4): 492-502
Published online Apr 15, 2020. doi: 10.4251/wjgo.v12.i4.492
Expression and significance of miR-654-5p and miR-376b-3p in patients with colon cancer
Ping Li, Jia-Xun Cai, Fei Han, Jie Wang, Jia-Jie Zhou, Kai-Wen Shen, Liu-Hua Wang
Ping Li, Department of Central Laboratory, Huaian Tumor Hospital & Huaian Hospital of Huaian City, Huaian 223200, Jiangsu Province, China
Ping Li, Department of General Surgery, Huaian Tumor Hospital & Huaian Hospital of Huaian City, Huaian 223200, Jiangsu Province, China
Jia-Xun Cai, Department of Anorectal, Clinical Medical College of Yangzhou University and Northern Jiangsu People’s Hospital, Yangzhou 225001, Jiangsu Province, China
Fei Han, Jie Wang, Jia-Jie Zhou, Kai-Wen Shen, Clinical Medical College, Yangzhou University, Yangzhou 225009, Jiangsu Province, China
Liu-Hua Wang, Department of General Surgery, General Surgery Institute of Yangzhou, Northern Jiangsu Province Hospital, Clinical Medical College, Yangzhou University, Yangzhou 225001, Jiangsu Province, China
Author contributions: Li P, Cai JX, Wang J and Han F contributed equally to this work. Li P, Wang J and Han F conceived, designed and drafted the paper; Wang LH provided supervision and review; Wang J and Han F conducted the statistical analyses; Zhou JJ and Shen KW contacted the authors of the included studies to obtain additional information; All of the authors approved the final version of the manuscript submitted for publication.
Institutional review board statement: This project was approved by the Clinical Research Ethics Committees of the participating institutions.
Clinical trial registration statement: This study is registered at clinical hospital center "Clinical Medical College of Yangzhou University (Northern Jiangsu Province Hospital)" Trial registry. The registration identification number is 2018KY-138.A separate document was uploaded as a proof of registry.
Informed consent statement: All study participants, or their legal guardian, provided written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Data sharing statement: There is no additional data available.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Liu-Hua Wang, FRCS (Hon), MD, Doctor, Surgeon, Department of General Surgery, General Surgery Institute of Yangzhou, Northern Jiangsu Province Hospital, Clinical Medical College, Yangzhou University, Nantong Road No. 98, Yangzhou 225001, Jiangsu Province, China. wlh1118ok@sina.com
Received: November 26, 2019
Peer-review started: November 26, 2019
First decision: January 14, 2020
Revised: February 5, 2020
Accepted: March 12, 2020
Article in press: March 12, 2020
Published online: April 15, 2020
Processing time: 140 Days and 19.5 Hours
Abstract
BACKGROUND

The relationship between microRNAs, such as miR-654-5p and miR-376b-3p, and the prognosis of colon cancer has not been studied until now.

AIM

To evaluate the expression levels of miR-654-5p and miR-376b-3p and their clinical significance in colon cancer.

METHODS

RT-qPCR was performed to evaluate miR-654-5p and miR-376b-3p expression in 34 pairs of colon cancer and adjacent noncancerous tissues. Subsequently, the association of miR-654-5p and miR-376b-3p expression with clinical factors or the survival of patients suffering from colon cancer was determined by using The Cancer Genome Atlas.

RESULTS

miR-654-5p was upregulated and miR-376b-3p was downregulated in colon cancer tissues compared with adjacent noncancerous tissues (P < 0.001). Increased miR-654-5p and decreased miR-376b-3p expression levels were significantly associated with metastasis and clinical stage. Moreover, a univariate analysis demonstrated that colon cancer patients with high miR-654-5p or low miR-376b-3p expression (P = 0.044 and 0.007, respectively) had a poor overall survival rate. A multivariate analysis identified high miR-654-5p expression and low miR-376b-3p expression as independent predictors of poor survival in colon cancer patients.

CONCLUSION

Upregulated miR-654-5p and downregulated miR-376b-3p may be associated with tumour progression in colon cancer, and these microRNAs may serve as independent prognostic markers for colon cancer.

Keywords: Colorectal cancer; Colon cancer; Rectal cancer; MiR-654-3p; MiR-376b-5p; Prognosis; Survival; The Cancer Genome Atlas

Core tip: This was a prospective study. The relationship between microRNAs, such as miR-654-5p and miR-376b-3p, and the prognosis of colon cancer has not been studied until now. In this present study, we found that upregulated miR-654-5p and downregulated miR-376b-3p may be associated with tumour progression in colon cancer, and these microRNAs may serve as independent prognostic markers for colon cancer.